Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon
I Can Extract Side Effects
Chapter 111

Orphan Drug Generic Plan

1,630 words 5 min read 2 views 4mo ago Source ​
Skip to the end of the chapter
Prev
Next

"Is Three Purities interested in developing generic versions of Clobazam?"

Upon hearing this question, Wei Kang was taken aback. He tapped his fingers lightly on the table and pondered, "We can make generic drugs, but whether or not to make them is a very complicated issue. Three Purities has always tended to solve problems at their root to achieve therapeutic effects."

"This relates to the company's strategic decisions, and I can't answer you right away. But I can say that if Three Purities wants to make generic drugs, it's not just Clobazam, but a series of Rare Disease drugs that it represents."

Jian Lianyun was both surprised and delighted, unsure of what to say, "Wei Kang, if that's really the case, that's wonderful. Thank you on behalf of the patients!"

Wei Kang told her to wait for news and then hung up the phone.

He searched for news about this incident and found that it was already a hot topic online. More than 20,000 families of sick children had joined together to publish a joint letter entitled "How Can We Keep Our Children Alive?", hoping to legally purchase Clobazam. The letter went viral online and, together with Chen Ping's suicide, moved countless netizens.

The joint letter stated. "At the end of the film 'Dying to Survive,' the protagonist Cheng Yong was released on parole. After his release, he learned that the drugs that led to his imprisonment for purchasing them had been included in medical insurance, and no one would face the problem of not being able to get their medication again. We hope that in the near future, our children will also be able to safely access Clobazam through legitimate channels!"

This is practically another version of "Dying to Survive," only it tells the story of a different drug— Clobazam.

Clobazam is a broad-spectrum anti-seizure drug that has been used to treat Rare Disease since the beginning of the century. It is very popular in the treatment of pediatric epilepsy because it has relatively few side effects compared to other similar drugs.

Seizures occur when there is an increase in excitatory neurotransmitters or a decrease in inhibitory neurotransmitters in the human brain. Clobazam, Benzodiazepine, increases inhibitory neurotransmitters in the brain, balancing them with excitatory neurotransmitters and thus preventing seizures.

The continuous seizures of epilepsy not only cause permanent brain damage but also pose a risk of suffocation and death. Once medication is stopped, each seizure will harm the child and cause permanent brain damage, leading to premature death.

In fact, the National Drug Administration Bureau had been promoting the research and development of Rare Disease drugs such as Clobazam for several years, but domestic pharmaceutical companies have not been very enthusiastic about the research and development of Rare Disease drugs.

This is not an isolated case. For a long time, the field of Rare Disease in China has been stagnant due to the limited development of the pharmaceutical industry. Data shows that the number of people with Rare Disease in China is approximately 16.8 million, many of whom are untreated and without access to effective treatments.

Rare Disease, also known as "Orphan Disease," refer to diseases with extremely low incidence rates. According to the World Health Organization (WHO), Rare Disease are defined as those affecting 0.65‰-1‰ of the total population.

Common Rare Disease include Albinism, Multiple Sclerosis, acromegaly, Idiopathic Pulmonary Hypertension, Phenylketonuria, and Mitochondrial Disease. Due to the small number of Rare Disease and the high research and development costs, pharmaceutical companies are not actively involved in developing drugs for Rare Disease, driven by economic considerations.

In the Eagle Country, for example, there were only 38 Orphan Drug on the market before 1983. In order to encourage pharmaceutical companies and support the development and application of drugs for Rare Disease, the Eagle Country. government enacted the Orphan Drug Act that year, which was also the world's first Orphan Drug Act.

Pharmaceutical companies that obtain Orphan Drug designation will receive a series of benefits, including government support for R&D funding, exemption from new drug application fees and drug marketing application fees, fast-track approval, priority consideration for research grant applications, tax breaks, and a 7-year market exclusivity right. Furthermore, applications for Orphan Drug designation can be submitted during the Animal Experiment phase.

Since the Orphan Drug Act was enacted, the FDA has granted 5,219 Orphan Drug designations over the past 30 years, with 843 drugs ultimately approved.

Given the significant impact of the Orphan Drug Act, countries around the world have subsequently enacted similar laws to encourage innovation in Orphan Drug.

With the advancement of technology, the emergence of novel treatments such as Gene Therapy, siRNA, and Immunotherapy has greatly promoted the research and development of drugs for Rare Disease. Currently, there are approximately 560 Rare Disease drug projects underway globally. In the past five years, the FDA has approved 15 Orphan Drug, marking new breakthroughs in the treatment of some intractable Rare Disease.

In 2019, China also approved eight Orphan Drug for marketing through expedited, priority, or conditional approval processes. Meanwhile, with the continuous improvement of the pharmaceutical industry, some domestic companies have begun to venture into the field of Rare Disease, entering the early exploration stage.

However, the development of drugs for Rare Disease in China remains fraught with difficulties. Not only are the research and Clinical Application challenging, but the most important reason is the high price of Rare Disease drugs and the small number of patients.

Because of the small number of Rare Disease, even if companies aim to fill the gap in clinical needs rather than make a profit, the drugs will inevitably be expensive in order to recoup costs.

For example, Novartis' Fingolimod, a drug for treating Multiple Sclerosis, is priced at 10,500 yuan per box in China. Although this price is not considered high globally, it is still unaffordable for many families.

In 2019, Zolgensma, a Gene Therapy drug for Spinal Muscular Atrophy, was approved for marketing in the Eagle Country. Priced at $2.1 million (approximately RMB 14.69 million), it is considered the most expensive drug in history and is beyond the reach of ordinary people.

These expensive original drugs cannot be copied in China due to patent restrictions. However, many drugs for Rare Disease have already had their patents expired, but no domestic companies have yet filed applications to copy them.

There are many reasons why pharmaceutical companies are unwilling to produce generic versions of Rare Disease drugs. These reasons are nothing more than the difficulty of technology, the high cost, and the small market size. In other words, the returns are far from ideal.

For example Deferasirox Dispersible Tablets, originally manufactured by Novartis, are recommended as a first-line treatment for iron overload in Thalassemia patients aged 6 years and older abroad. However, the annual sales of this original drug in sampled public hospitals in China were only 8.74 million yuan.

For example, Clobazam is urgently needed by only tens of thousands of patients in China, and each box costs only three or four hundred yuan when purchased through a proxy. If domestic pharmaceutical companies were to produce it, it would be strange if they didn't lose money. No wonder pharmaceutical companies have no incentive to produce generic versions.

But isn't there the Three Purities?

Three Purities has the technology and capital. The difficulties encountered by other pharmaceutical companies are not a problem for Wei Kang at all. As long as he wants to do it, he will definitely be able to do it.

Let's start with generic drugs for Rare Disease, which are easier to use. The first one is Clobazam, which can solve the urgent needs of parents of children with rare diseases.

Once the generic drugs are ready, we can then develop original drugs for other Rare Disease.

He summoned Li Zhong, his former subordinate, who had always worked diligently. It was most appropriate for him to handle the relatively low-tech task of generic drug development.

"First, you gather information and make a list of Rare Disease and their treatments worldwide, marking out those original drugs whose patents have expired. I need that information."

Li Zhong remained as diligent and honest as ever, adjusted his glasses, and nodded in agreement.

Wei Kang thought for a moment and then added a few more words, "Three Purities is going to launch a generic drug production plan for Rare Disease. The first one is Clobazam, and then we will prioritize selecting all children's drugs and make an urgent list."

"You should start preparing the necessary documents and submit the project application for the generic version of Clobazam. Do it as soon as possible!"

Watching Li Zhong leave, Wei Kang sent a message to Jian Lianyun informing her of his decision, as a reply to her.

He then posted the story online.

"The recent Clobazam incident touched me deeply. While Three Purities has conquered Cancer and Alzheimer's disease, there are still many Rare Disease who are fighting against their illnesses in order to survive."

"This shouldn't be the case. All diseases in the world should be treated equally. We shouldn't stop or even give up just because there are fewer patients with a certain disease and the research and development costs are high. Especially since many drugs are not patent-related and can be saved simply by using generic versions."

"At this time, Three Purities, as a member of the pharmaceutical industry, should shoulder its due responsibility and provide affordable and high-quality generic drugs for patients with Rare Disease in China."

"Three Purities has launched a plan to bring generic drugs for Rare Disease to market. We will invest resources in the generic development of Orphan Drug, starting with Clobazam. The project has already been initiated, and we will do our best to bring it to market as soon as possible so that all patients can buy the drugs they need through legitimate channels."

"This is the philosophy of Three Purities: to make medicines for the needs of society."

Thank you to Wang Duan for the 3000 reward, I am a policewoman for the 100 reward, and SloppyZ for the 100 reward.

End of Chapter
Prev
NovelSummaries
Next

Explore the wiki

Wei Kang
Three Purities
Eagle Country

Comments

No comments yet.
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS